ClinConnect ClinConnect Logo
Search / Trial NCT06712017

Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China

Launched by GRANDPHARMA (CHINA) CO., LTD. · Nov 26, 2024

Trial Information

Current as of July 23, 2025

Enrolling by invitation

Keywords

Yttrium 90 Y 90 Hcc Sirt

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. age ≥ 18 years old;
  • 2. confirmed diagnosis of HCC
  • 3. treated with yttrium-90 during 2023.1.1 - 2024.6.30 and assessed at least once for tumor response within 6 months following treatment
  • Exclusion Criteria:
  • no formal exclusion criteria in a real-world study

About Grandpharma (China) Co., Ltd.

Grandpharma (China) Co., Ltd. is a leading biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapeutics across various therapeutic areas. Established with a commitment to enhancing global health, Grandpharma leverages advanced technologies and a robust pipeline to address unmet medical needs. The company emphasizes quality and compliance throughout its operations, aiming to deliver safe and effective solutions to patients worldwide. With a strong focus on clinical research and collaboration, Grandpharma is poised to make significant contributions to the advancement of healthcare both in China and internationally.

Locations

Guangzhou, Guangdong, China

Beijing, , China

Shanghai, , China

Jinan, Guangdong, China

Xi'an, Guangxi, China

Xi'an, Shanxi, China

Patients applied

0 patients applied

Trial Officials

Xiaobin Feng, MD

Principal Investigator

Beijing Tsinghua Changgeng Hospital

Kangshun Zhu, MD

Principal Investigator

Second Affiliated Hospital of Guangzhou Medical University

Yefa Yang, MD

Principal Investigator

The Third Affiliated Hospital of Naval Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported